July 22, 2026 11:32 AM EDT
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
Arrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population.
Data
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.







